ABSTRACT
Genomic profiling of hematologic malignancies has augmented our understanding of variants that contribute to disease pathogenesis and supported development of prognostic models that inform disease management in the clinic. Tumor only sequencing assays are limited in their ability to identify definitive somatic variants, which can lead to ambiguity in clinical reporting and patient management. Here, we describe the MSK-IMPACT Heme cohort, a comprehensive data set of somatic alterations from paired tumor and normal DNA using a hybridization capture-based next generation sequencing platform. We highlight patterns of mutations, copy number alterations, and mutation signatures in a broad set of myeloid and lymphoid neoplasms. We also demonstrate the power of appropriate matching to make definitive somatic calls, including in patients who have undergone allogeneic stem cell transplant. We expect that this resource will further spur research into the pathobiology and clinical utility of clinical sequencing for patients with hematologic neoplasms.
Competing Interest Statement
Ryan N. Ptashkin is an employee of C2i Genomics. Gowtham Jayakumaran is an employee of Guardant Health. Chad Vanderbilt reports intellectual property rights and equity interest in Paige.AI, Inc. Menglei Zhu has received advisory or consulting fees from Leica Biosystems. Jae Park has received advisory or consulting fees from Allogene, Amgen, Artiva, Autolus, BMS, Curocel, Incyte, InnatePharma, Kite Pharma, Kura Oncology, Minerva, Novartis, Pfizer, PrecisionBio, Servier, and served on a data monitoring committee for Affyimmune, BrightPharma and Intellia. Omar Abdel-Wahab has served as a consultant for H3B Biomedicine, Foundation Medicine Inc, Merck, and Janssen, and is on the Scientific Advisory Board of Pfizer Boulder, Envisagenics Inc., and AIChemy; O.A.-W. has received prior research funding from H3B Biomedicine, Loxo/Lilly, and Nurix Therapeutics unrelated to the current manuscript. Anthony Mato has received research funding from TG Therapeutics, Pharmacyclics, AbbVie, Johnson and Johnson, Astra Zeneca, DTRM BioPharma, BeiGene, Genentech, Genmab Janssen, LOXO, Nurix, Octopharma, Pfizer and has received honoraria from TG Therapeutics, Pharmacyclics LLC, AbbVie, Adaptive Biotechnologies, Johnson and Johnson AcertaDTRM BioPharma, Nurix, AstraZeneca BeiGene Genentech Janssen LOXO, Curio, Dava, Octopharma, Genmab, BMS, Medscape, PER, PerView. Mikhail Roshal has received research funding from Roche, NGM, and Beat AML and has served on an advisory board and holds stock/stock options in Auron Therapeutics. Mariko Yabe has served as a consultant for Janssen R&D. Connie Batlevi has received advisory or consulting fees from ADC Therapeutics, AbbVie, Bristol-Myers Squibb, Dava Oncology, Defined Health, Epizyme, Gerson Lehrman Group, Juno Therapeutics, Karyopharm, Kite Pharmaceuticals, LifeSci Capital, LLC, Medscape, MorphoSys AG, NeuroAxis LLC, Seattle Genetics, Skipta LLC, TG Therapeutics, Inc, Touch Independent Medical Education Ltd, and Treeline Biosciences, Inc., and reports ownership/equity interest in Bristol-Myers Squibb, Moderna, Inc., Novavax, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Viatris Inc. Sergio Giralt has received advisory or consulting fees from Amgen, CSL Behring, Caladrius, Celgene, Ceramedix, ExpertConnect, GlaxoSmithKline, Janssen Research & Development, LLC, Karyopharm, Kite Pharmaceuticals, Magnolia Innovation, Novartis, Omeros, Pfizer, Inc., Physicians' Education Resource, Sanofi US Services Inc., TRM Oncology, and Xcenda. Gilles Salles has received advisory or consulting fees from Abbvie, Beigene, Bayer, BMS/Celgene, Epizyme, Genentech/Roche, Genmab, Incyte, Ipsen, Janssen, Kite/Gilead, Loxo, Milteniy, Molecular Partners, Morphosys, Nordic Nanovector, Novartis, Rapt, Regeneron, and Takeda, and reports equity interest in Owkin. Raajit Rampal has received advisory or consulting fees from Constellation, Incyte, Celgene/BMS, Novartis, Promedior, CTI, Jazz Pharmaceuticals, Blueprint, Stemline, Galecto, PharmaEssentia, AbbVie, Sierra Oncology, Servier, and Disc Medicines; and research funding from Incyte, Constellation, and Stemline Eytan Stein has received advisory or consulting fees from AbbVie, Agios Pharmaceuticals, Bristol-Myers Squibb, CTI BioPharma Corp., Calithera, Celgene, Epizyme, Genentech, Genesis Therapeutics, Gilead Pharmaceutical, Janssen Pharmaceuticals, Inc., Jazz Pharmaceuticals, Kronos Bio, Inc, Kura Oncology, Neoleukin Therapeutics, Inc., Novartis Pharmaceuticals Corporation, PinotBio, Inc., Servier, Syndax, and Takeda Millennium, and reports ownership/equity interests in Auron Therapeutics, Inc. Anas Younes is an employee of AstraZeneca. Ross Levine is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Syndax. Zentalis, Ajax, Bakx, Auron, Prelude, C4 Therapeutics and Isoplexis for which he receives equity support. RLL receives research support from Ajax and Abbvie and has consulted for Incyte, Janssen, Morphosys and Novartis. He has received honoraria from Astra Zeneca and Kura for invited lectures. Miguel Perales reports honoraria from Abbvie, Allovir, Astellas, Bristol-Myers Squibb, Caribou Biosciences, Celgene, Equilium, Exevir, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Novartis, Nektar Therapeutics, Omeros, OrcaBio, Takeda, and VectivBio AG, Vor Biopharma. He serves on DSMBs for Cidara Therapeutics, Medigene, Sellas Life Sciences, and Servier, and the scientific advisory board of NexImmune. He has ownership interests in NexImmune and Omeros. He has received institutional research support for clinical trials from Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. Marcel van den Brink has received advisory or consulting fees from Ceramedix, DKMS, Da Volterra, Garuda Therapeutics, GlaxoSmithKline, LyGenesis, Inc., Vor Biopharma, Pluto Immunotherapeutics, Rheos Medicines, Inc, Seres Therapeutics, Frazier Healthcare Partners, and Notch Therapeutics and has ownership/equity interests in Pluto Immunotherapeutics, Seres Therapeutics, ThymoFox, Inc., and Notch Therapeutics. He is in a fiduciary role/position for DKMS, holds intellectual property rights with Juno Therapeutics and Seres Therapeutics, and has received royalties from Wolters Kluwer. Ahmet Dogan has received advisory or consulting fees from Incyte, Loxo Oncology, and Physicians' Education Resource and has received research funding from Roche and Takeda. Marc Ladanyi has received advisory or consulting fees from Takeda Oncology, Janssen Pharmaceuticals. Consulting or Advisory Role: AstraZeneca, ADC Therapeutics, Paige.AI, Merck, Bayer, and Lilly Oncology and has received research funding from Loxo Oncology, Helsinn Therapeutics, Merus NV, Elevation Oncology, and Rain Therapeutics. Michael Berger has received advisory or consulting fees from AstraZeneca, Eli Lilly and Company, and PetDx, Inc. A. Rose Brannon has ownership/equity interests in Johnson and Johnson. Ryma Benayed is an employee of AstraZeneca. Ahmet Zehir is an employee of AstraZeneca. Maria Arcila has received advisory or consulting fees from Axis Medical Education, Clinical Education Alliance, LLC, Merck Sharp & Dohme, PeerView Institute for Medical Education (PVI), Physicians' Education Resource, RMEI Medical Education, LLC, and Roche.
Funding Statement
This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Memorial Sloan Kettering Cancer Center gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors